NQO1-Mediated tumor-selective lethality and radiosensitization for head and neck cancer

Long Shan Li, Srilakshmi Reddy, Zhen Hua Lin, Shuangping Liu, Hyunsil Park, Stephen G. Chun, William G. Bornmann, Joel Thibodeaux, Jingsheng Yan, Gaurab Chakrabarti, Xian Jin Xie, Baran D. Sumer, David A. Boothman, John S. Yordy

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Ionizing radiation (IR) is a key therapeutic regimen for many head and neck cancers (HNC). However, the 5-year overall survival rate for locally advanced HNCs is approximately 50% and better therapeutic efficacy is needed. NAD(P)H:quinone oxidoreductase 1 (NQO1) is overexpressed in many cancers, and b-lapachone (b-lap), a unique NQO1 bioactivatable drug, exploits this enzyme to release massive reactive oxygen species (ROS) that synergize with IR to kill by programmed necrosis. b-Lap represents a novel therapeutic opportunity in HNC leading to tumor-selective lethality that will enhance the efficacy of IR. Immunohistochemical staining and Western blot assays were used to assess the expression levels of NQO1 in HNC cells and tumors. Forty-five percent of endogenous HNCs expressed elevated NQO1 levels. In addition, multiple HNC cell lines and tumors demonstrated elevated levels of NQO1 expression and activity and were tested for anticancer lethality and radiosensitization by b-lap using long-term survival assays. The combination of nontoxic b-lap doses and IR significantly enhanced NQO1-dependent tumor cell lethality, increased ROS, TUNEL-positive cells, DNA damage, NAD? , and ATP consumption, and resulted in significant antitumor efficacy and prolonged survival in two xenograft murine HNC models, demonstrating b-lap radiosensitization of HNCs through a NQO1-dependent mechanism. This translational study offers a potential biomarker-driven strategy using NQO1 expression to select tumors susceptible to b-lap-induced radiosensitization.

Original languageEnglish (US)
Pages (from-to)1757-1767
Number of pages11
JournalMolecular Cancer Therapeutics
Volume15
Issue number7
DOIs
StatePublished - Jul 1 2016

Fingerprint

Head and Neck Neoplasms
Ionizing Radiation
Neoplasms
NAD
Reactive Oxygen Species
In Situ Nick-End Labeling
Tumor Cell Line
Heterografts
DNA Damage
Oxidoreductases
Necrosis
Therapeutics
Adenosine Triphosphate
Biomarkers
Western Blotting
Staining and Labeling
Enzymes
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

NQO1-Mediated tumor-selective lethality and radiosensitization for head and neck cancer. / Li, Long Shan; Reddy, Srilakshmi; Lin, Zhen Hua; Liu, Shuangping; Park, Hyunsil; Chun, Stephen G.; Bornmann, William G.; Thibodeaux, Joel; Yan, Jingsheng; Chakrabarti, Gaurab; Xie, Xian Jin; Sumer, Baran D.; Boothman, David A.; Yordy, John S.

In: Molecular Cancer Therapeutics, Vol. 15, No. 7, 01.07.2016, p. 1757-1767.

Research output: Contribution to journalArticle

Li, Long Shan ; Reddy, Srilakshmi ; Lin, Zhen Hua ; Liu, Shuangping ; Park, Hyunsil ; Chun, Stephen G. ; Bornmann, William G. ; Thibodeaux, Joel ; Yan, Jingsheng ; Chakrabarti, Gaurab ; Xie, Xian Jin ; Sumer, Baran D. ; Boothman, David A. ; Yordy, John S. / NQO1-Mediated tumor-selective lethality and radiosensitization for head and neck cancer. In: Molecular Cancer Therapeutics. 2016 ; Vol. 15, No. 7. pp. 1757-1767.
@article{aa6c0c7461a54fe6951f0cd3d56b8b77,
title = "NQO1-Mediated tumor-selective lethality and radiosensitization for head and neck cancer",
abstract = "Ionizing radiation (IR) is a key therapeutic regimen for many head and neck cancers (HNC). However, the 5-year overall survival rate for locally advanced HNCs is approximately 50{\%} and better therapeutic efficacy is needed. NAD(P)H:quinone oxidoreductase 1 (NQO1) is overexpressed in many cancers, and b-lapachone (b-lap), a unique NQO1 bioactivatable drug, exploits this enzyme to release massive reactive oxygen species (ROS) that synergize with IR to kill by programmed necrosis. b-Lap represents a novel therapeutic opportunity in HNC leading to tumor-selective lethality that will enhance the efficacy of IR. Immunohistochemical staining and Western blot assays were used to assess the expression levels of NQO1 in HNC cells and tumors. Forty-five percent of endogenous HNCs expressed elevated NQO1 levels. In addition, multiple HNC cell lines and tumors demonstrated elevated levels of NQO1 expression and activity and were tested for anticancer lethality and radiosensitization by b-lap using long-term survival assays. The combination of nontoxic b-lap doses and IR significantly enhanced NQO1-dependent tumor cell lethality, increased ROS, TUNEL-positive cells, DNA damage, NAD? , and ATP consumption, and resulted in significant antitumor efficacy and prolonged survival in two xenograft murine HNC models, demonstrating b-lap radiosensitization of HNCs through a NQO1-dependent mechanism. This translational study offers a potential biomarker-driven strategy using NQO1 expression to select tumors susceptible to b-lap-induced radiosensitization.",
author = "Li, {Long Shan} and Srilakshmi Reddy and Lin, {Zhen Hua} and Shuangping Liu and Hyunsil Park and Chun, {Stephen G.} and Bornmann, {William G.} and Joel Thibodeaux and Jingsheng Yan and Gaurab Chakrabarti and Xie, {Xian Jin} and Sumer, {Baran D.} and Boothman, {David A.} and Yordy, {John S.}",
year = "2016",
month = "7",
day = "1",
doi = "10.1158/1535-7163.MCT-15-0765",
language = "English (US)",
volume = "15",
pages = "1757--1767",
journal = "Molecular Cancer Therapeutics",
issn = "1535-7163",
publisher = "American Association for Cancer Research Inc.",
number = "7",

}

TY - JOUR

T1 - NQO1-Mediated tumor-selective lethality and radiosensitization for head and neck cancer

AU - Li, Long Shan

AU - Reddy, Srilakshmi

AU - Lin, Zhen Hua

AU - Liu, Shuangping

AU - Park, Hyunsil

AU - Chun, Stephen G.

AU - Bornmann, William G.

AU - Thibodeaux, Joel

AU - Yan, Jingsheng

AU - Chakrabarti, Gaurab

AU - Xie, Xian Jin

AU - Sumer, Baran D.

AU - Boothman, David A.

AU - Yordy, John S.

PY - 2016/7/1

Y1 - 2016/7/1

N2 - Ionizing radiation (IR) is a key therapeutic regimen for many head and neck cancers (HNC). However, the 5-year overall survival rate for locally advanced HNCs is approximately 50% and better therapeutic efficacy is needed. NAD(P)H:quinone oxidoreductase 1 (NQO1) is overexpressed in many cancers, and b-lapachone (b-lap), a unique NQO1 bioactivatable drug, exploits this enzyme to release massive reactive oxygen species (ROS) that synergize with IR to kill by programmed necrosis. b-Lap represents a novel therapeutic opportunity in HNC leading to tumor-selective lethality that will enhance the efficacy of IR. Immunohistochemical staining and Western blot assays were used to assess the expression levels of NQO1 in HNC cells and tumors. Forty-five percent of endogenous HNCs expressed elevated NQO1 levels. In addition, multiple HNC cell lines and tumors demonstrated elevated levels of NQO1 expression and activity and were tested for anticancer lethality and radiosensitization by b-lap using long-term survival assays. The combination of nontoxic b-lap doses and IR significantly enhanced NQO1-dependent tumor cell lethality, increased ROS, TUNEL-positive cells, DNA damage, NAD? , and ATP consumption, and resulted in significant antitumor efficacy and prolonged survival in two xenograft murine HNC models, demonstrating b-lap radiosensitization of HNCs through a NQO1-dependent mechanism. This translational study offers a potential biomarker-driven strategy using NQO1 expression to select tumors susceptible to b-lap-induced radiosensitization.

AB - Ionizing radiation (IR) is a key therapeutic regimen for many head and neck cancers (HNC). However, the 5-year overall survival rate for locally advanced HNCs is approximately 50% and better therapeutic efficacy is needed. NAD(P)H:quinone oxidoreductase 1 (NQO1) is overexpressed in many cancers, and b-lapachone (b-lap), a unique NQO1 bioactivatable drug, exploits this enzyme to release massive reactive oxygen species (ROS) that synergize with IR to kill by programmed necrosis. b-Lap represents a novel therapeutic opportunity in HNC leading to tumor-selective lethality that will enhance the efficacy of IR. Immunohistochemical staining and Western blot assays were used to assess the expression levels of NQO1 in HNC cells and tumors. Forty-five percent of endogenous HNCs expressed elevated NQO1 levels. In addition, multiple HNC cell lines and tumors demonstrated elevated levels of NQO1 expression and activity and were tested for anticancer lethality and radiosensitization by b-lap using long-term survival assays. The combination of nontoxic b-lap doses and IR significantly enhanced NQO1-dependent tumor cell lethality, increased ROS, TUNEL-positive cells, DNA damage, NAD? , and ATP consumption, and resulted in significant antitumor efficacy and prolonged survival in two xenograft murine HNC models, demonstrating b-lap radiosensitization of HNCs through a NQO1-dependent mechanism. This translational study offers a potential biomarker-driven strategy using NQO1 expression to select tumors susceptible to b-lap-induced radiosensitization.

UR - http://www.scopus.com/inward/record.url?scp=84979282977&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84979282977&partnerID=8YFLogxK

U2 - 10.1158/1535-7163.MCT-15-0765

DO - 10.1158/1535-7163.MCT-15-0765

M3 - Article

VL - 15

SP - 1757

EP - 1767

JO - Molecular Cancer Therapeutics

JF - Molecular Cancer Therapeutics

SN - 1535-7163

IS - 7

ER -